Clinical Trials Browser

Has results × Capecitabine × 1 year × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Pancreatic Intraductal Neoplasms

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Rectal Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

Fallopian Tube Neoplasms, Ovarian Neoplasms

Triple Negative Breast Neoplasms

Esophageal Neoplasms, Stomach Neoplasms

Pancreatic Neoplasms

Adenocarcinoma, Neoplasms, Stomach Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Meningeal Neoplasms

Locally Advanced and Metastatic Solid Tumors

Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Esophageal Squamous Cell Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Colonic Neoplasms

Adenocarcinoma, Gastrointestinal Neoplasms, Neoplasm Metastasis

Clinical Trials

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

KEYNOTE-585

DB-06

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

GLOW

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

MK-7119-001

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

LEAP-009

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

IMpassion132

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

DisTinGuish

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

CheckMate649

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

PERSEVERE

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer